AllSci News
Teva reports early vitiligo data for anti-IL-15 TEV-'408, advances into Phase IIb
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) reported Phase Ib data for TEV-'408, its internally discovered anti-IL-15 monoclonal antibody, and...
HMNC reports peer-reviewed oral ketamine data showing reduced dissociation in treatment-resistant depression
Germany-based HMNC Brain Health (HMNC Holding GmbH) reported peer-reviewed results from the Ketabon KET01 clinical trial program in JAMA Network Open on...
Saol Therapeutics resubmits rare mitochondrial disease drug after FDA agreement
Roswell, Georgia-based Saol Therapeutics has resubmitted its New Drug Application (NDA) to the US FDA for SL1009 (sodium dichloroacetate, or DCA), seeking...
MeiraGTx secures USD 400m from Oberland Capital to fund gene therapy commercialization
UK-based MeiraGTx Holdings plc (Nasdaq: MGTX) announced a strategic investment of up to USD 400 million from Oberland Capital Management LLC, structured to...
Organogenesis advances first amniotic tissue biologic to FDA review for knee osteoarthritis
The US FDA's acceptance of a Biologics License Application (BLA) for Amnuvx (azimplacel, formerly Renu) — a cryopreserved amniotic suspension allograft for...
Kalohexis files confidential IPO as oral non-GLP-1 obesity biotech enters public markets
Northbrook, Illinois-based Kalohexis, Inc. — a clinical-stage biotechnology company targeting the melanocortin receptor system for obesity and cancer...
FDA grants priority review to Agios’ mitapivat as first oral PK activator for sickle cell disease
Agios Pharmaceuticals (Nasdaq: AGIO) announced that the US FDA has granted Priority Review to its supplemental New Drug Application (sNDA) for mitapivat…
Abivax secures USD 920m to fund US launch of inflammatory bowel disease candidate
France-based Abivax SA (Euronext Paris / Nasdaq: ABVX) announced the closing of a USD 920 million (EUR 807 million) Abivax public offering of American...
Pharvaris advances first bradykinin B2 antagonist for on-demand HAE treatment to FDA review
Pharvaris N.V. (Nasdaq: PHVS) has submitted a New Drug Application to the US FDA for deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand...
MGI Tech's ProtoPilot closes the gap between AI reasoning and wet-lab execution
MGI Tech's subsidiary Genoria AI, in partnership with the Shanghai Artificial Intelligence Laboratory, launched ProtoPilot and BioLab Bench on July 5 — a...
Henry Ford Health secures NIH funding for inhaled IPF therapy based on vonoprazan
Henry Ford Health + Michigan State University Health Sciences has received a USD 1.56 million NIH R01 grant from the National Heart, Lung, and Blood...
VCU advances dual EGFR/HER2 degradation strategy to overcome drug resistance in lung cancer
Virginia Commonwealth University has received a USD 1.74 million National Cancer Institute R01 award to advance preclinical evaluation of PEPDG278D, a...
Broad Institute advances gene editing to permanently lower prion protein and halt neurodegeneration
The Broad Institute has received a USD 11.3 million NIH U19 renewal to advance gene editing approaches aimed at permanently lowering prion protein (PrP)...
Aureka open-sources biomolecular foundation model for AI drug discovery
Laguna Hills, California-based Aureka has released OpenDDE, an open-source, all-atom biomolecular foundation model designed to serve as a structural...
Beckman Coulter's CE-marked p-Tau217 blood test enables scalable Alzheimer's screening in routine labs
Beckman Coulter Diagnostics has received CE Mark under IVDR for its Access p-Tau217 blood test and simultaneously unveiled a companion research assay, the...
The AllSci Brief
Free, systematic R&D and deal news. Daily.